Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1. doi: 10.1200/JCO.2005.04.4420.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Clinical Trials, Phase II as Topic
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Gene Deletion
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Point Mutation
  • Predictive Value of Tests
  • Prognosis
  • Protein Kinase Inhibitors / pharmacology
  • Quinazolines / pharmacology*
  • Quinazolines / therapeutic use
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors